|
|
Sarepta Therapeutics Inc (NASDAQ: SRPT) |
|
Price: $123.1300
$-1.34 
-1.077%
|
| Day's High:
| $123.4567
| Week Perf:
| -4.76 %
|
| Day's Low: |
$ 122.13 |
30 Day Perf: |
2.25 % |
| Volume (M): |
16 |
52 Wk High: |
$ 173.25 |
| Volume (M$): |
$ 1,952 |
52 Wk Avg: |
$126.85 |
| Open: |
$123.19 |
52 Wk Low: |
$89.92 |
|
|
| Market Capitalization (Millions $) |
12,368 |
| Shares
Outstanding (Millions) |
100 |
| Employees |
1,314 |
| Revenues (TTM) (Millions $) |
1,640 |
| Net Income (TTM) (Millions $) |
122 |
| Cash Flow (TTM) (Millions $) |
-348 |
| Capital Exp. (TTM) (Millions $) |
128 |
Sarepta Therapeutics Inc
Sarepta Therapeutics Inc is a biotechnology company that specializes in developing therapies for rare genetic diseases. The company is based in Cambridge, Massachusetts, and was founded in 1980.
Sarepta Therapeutics Inc focuses on developing and commercializing drugs for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disease that affects about 1 in every 3,500 males worldwide. The company's lead product candidate is a drug called eteplirsen, which is designed to treat DMD by repairing the genetic defects that cause the disease.
The company has a strong pipeline of other promising therapies, including drugs for the treatment of other types of muscular dystrophy and rare diseases such as limb-girdle muscular dystrophy, myotonic dystrophy, and spinal muscular atrophy.
Sarepta Therapeutics Inc has a robust research and development team made up of scientists, clinicians, and other experts with extensive experience in the field of genetic disease. The company has also built strong partnerships with academic institutions and other biotechnology companies, enabling it to access cutting-edge research and technology.
In addition to its drug development activities, Sarepta Therapeutics Inc is active in patient advocacy and education. The company works closely with patient advocacy groups and medical professionals to raise awareness about rare genetic diseases and to provide support to affected families. The company also sponsors research and educational programs, and provides financial assistance to families in need.
Sarepta Therapeutics Inc has a strong financial position, with a market capitalization of over $12 billion as of 2021, and a track record of revenue growth. The company has a broad investor base, including institutional investors, private equity firms, and individual investors.
Overall, Sarepta Therapeutics Inc is a successful biotechnology company that has made significant progress in developing therapies for rare genetic diseases. With its strong pipeline, experienced team, and commitment to patient advocacy, the company is well positioned for future growth and success.
Company Address: 215 First Street Cambridge 2142 MA
Company Phone Number: 274-4000 Stock Exchange / Ticker: NASDAQ SRPT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, Nov 26 2024 2:47 PM UTC
Harnessing the Power of Precision Medicine: Sarepta Therapeutics and Arrowhead Pharmaceuticals Forge Strategic Alliance Amidst Record-Breaking Financial Performance Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a trailblazer in the realm of precision genetic medicine for rare diseases, today revealed a major strategic initiative designed to further cement its leadership positio...
|
| Business Update
Published Fri, Nov 1 2024 12:36 AM UTC
Abstract: Sarepta Therapeutics, a trailblazer in the realm of precision genetic medicine, made a significant stride in fortifying its workforce and commitment to therapeutic innovations by granting equity awards under Nasdaq Listing Rule 5635(c)(4). These awards, as announced on October 31, 2024, were strategically allocated to 15 new hires under Sarepta?s 2024 Employment Co...
|
| Business Update
Published Thu, Oct 31 2024 9:36 PM UTC
Precision Medicine Moves Forward: Sarepta Therapeutics Announces Inducement Grants and Continued Market Success In a bold stride towards bolstering its talent pool and reaffirming its industry prowess, Sarepta Therapeutics, Inc. (NASDAQ: SRPT) the unrivaled leader in precision genetic medicine for rare diseases has announced the granting of new equity awards. These awards, d...
|
| Business Update
Published Tue, Oct 1 2024 12:47 AM UTC
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), continues to forge ahead as a paragon in the field of precision genetic medicine for rare diseases. The recent announcements regarding corporate developments, presentation of new data, and financial results underscore the company?s commitment to innovation and growth. This article will delve into these latest strides, showcasing how ...
|
| Business Update
Published Mon, Sep 30 2024 11:47 PM UTC
In the esteemed town of Cambridge, Massachusetts, on the thirtieth day of September in the year of our Lord two thousand and twenty-four, the illustrious institution, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), hath made an announcement of considerable import. Renowned as a paragon in the domain of precision genetic medicine, particularly concerning rare maladies, this distin...
|
| Per Share |
Current |
| Earnings (TTM) |
1.21 $ |
| Revenues (TTM) |
16.33 $
|
| Cash Flow (TTM) |
- |
| Cash |
11.93 $
|
| Book Value |
12.16 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
1.21 $
|
| Revenues (TTM) |
16.33 $ |
| Cash Flow (TTM) |
- |
| Cash |
11.93 $
|
| Book Value |
12.16 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| PMO Products |
|
 53.25 % |
of total Revenue |
| PMO Products United States |
|
45.1 % |
of total Revenue |
| PMO Products Rest of World |
|
8.16 % |
of total Revenue |
| ELEVIDYS |
|
38.74 % |
of total Revenue |
| ELEVIDYS United States |
|
38.74 % |
of total Revenue |
| |
On January 8 2024 the Sarepta Therapeutics Inc provided following guidance
to be $175.8 million and $573.1 million, respectively.
Sarepta Therapeutics, a pioneering company in precision genetic medicine for rare diseases, announced its preliminaryn net product revenue for the fourth quarter and full-year 2023. The announcement was made during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
According to the preliminaryn and unaudited financial update, Sarepta Therapeutics expects the net product revenue for their flagship product, ELEVIDYS, to reach $175.8 million for the fourth quarter of 2023. The full-year net product revenue for ELEVIDYS is projected to be $573.1 million.
These estimates provide insights into the company's ...
|
|
|
0.82%